Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors

BACKGROUND: cKIT kinase overexpression and gain-of-function mutations are the critical pathogenesis of gastrointestinal stromal tumors (GISTs). Although the multiple kinase inhibitors such as imatinib, sunitinib, and regorafenib have been approved for GISTs, the acquisition of polyclonal secondary r...

Full description

Saved in:
Bibliographic Details
Published in:Ther Adv Med Oncol
Main Authors: Liu, Feiyang, Zou, Fengming, Chen, Cheng, Yu, Kailin, Liu, Xiaochuan, Qi, Shuang, Wu, Jiaxin, Hu, Chen, Hu, Zhenquan, Liu, Juan, Liu, Xuesong, Wang, Li, Ge, Juan, Wang, Wenchao, Ren, Tao, Bai, Mingfeng, Cai, Yujiao, Xiao, Xudong, Qian, Feng, Tang, Jun, Liu, Qingsong, Liu, Jing
Format: Artigo
Language:Inglês
Published: SAGE Publications 2019
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6535728/
https://ncbi.nlm.nih.gov/pubmed/31205508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919849757
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items